The identification of mechanisms regulating the hallmarks of this aggressive disease and of candidate molecules (Notch, TGFβ and Shh ligands and their effectors) with the potential to interfere with cancer progression is an important step towards new therapies for pancreatic adenocarcinoma. Here, SHH is linked to pancreatic adenocarcinoma.